NO20083065L - New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions - Google Patents

New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions

Info

Publication number
NO20083065L
NO20083065L NO20083065A NO20083065A NO20083065L NO 20083065 L NO20083065 L NO 20083065L NO 20083065 A NO20083065 A NO 20083065A NO 20083065 A NO20083065 A NO 20083065A NO 20083065 L NO20083065 L NO 20083065L
Authority
NO
Norway
Prior art keywords
sulfamoylpiperidinamides
prophylaxis
obesity
treatment
new
Prior art date
Application number
NO20083065A
Other languages
Norwegian (no)
Inventor
Jochen Antel
Uwe Schoen
Harald Waldeck
Michael Wurl
Michael Firnges
Dania Reiche
Peter-Colin Gregory
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20083065L publication Critical patent/NO20083065L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Den foreliggende oppfinnelse vedrører nye N-sulfaraoylpiperidinamider med generell formel (I): og deres fysiologisk akseptable syre-addisjonssalter, farmasøytiske preparater som omfatter dem, fremgangsmåter for deres fremstilling, og deres anvendelse til behandling av overvekt og ledsagende og/eller sekundære sykdommer og/eller beslektede tilstander.The present invention relates to novel N-sulfaraoylpiperidinamides of general formula (I): or related conditions.

NO20083065A 2005-12-09 2008-07-08 New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions NO20083065L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05111882 2005-12-09
PCT/EP2006/069482 WO2007065948A1 (en) 2005-12-09 2006-12-08 Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions

Publications (1)

Publication Number Publication Date
NO20083065L true NO20083065L (en) 2008-09-04

Family

ID=36222433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083065A NO20083065L (en) 2005-12-09 2008-07-08 New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions

Country Status (12)

Country Link
EP (1) EP1960359A1 (en)
JP (1) JP2009518366A (en)
KR (1) KR20080074217A (en)
CN (1) CN101326166A (en)
AU (1) AU2006323952A1 (en)
BR (1) BRPI0619583A2 (en)
CA (1) CA2632719A1 (en)
IL (1) IL192025A0 (en)
NO (1) NO20083065L (en)
RU (1) RU2442773C2 (en)
WO (1) WO2007065948A1 (en)
ZA (1) ZA200804077B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
NZ579229A (en) 2007-01-25 2011-07-29 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
CN102427810A (en) * 2009-05-01 2012-04-25 拉夸里亚创药株式会社 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN106546740B (en) * 2016-10-27 2019-04-09 暨南大学 Detection of the CA2 in nasopharyngeal carcinoma, treatment application
WO2018237026A1 (en) * 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440383A (en) * 2000-04-28 2003-09-03 三共株式会社 PPAR gamma modulators
US6946476B2 (en) * 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists

Also Published As

Publication number Publication date
IL192025A0 (en) 2008-12-29
CN101326166A (en) 2008-12-17
AU2006323952A1 (en) 2007-06-14
EP1960359A1 (en) 2008-08-27
WO2007065948A1 (en) 2007-06-14
BRPI0619583A2 (en) 2011-10-04
ZA200804077B (en) 2009-10-28
RU2008127442A (en) 2010-01-20
CA2632719A1 (en) 2007-06-14
JP2009518366A (en) 2009-05-07
RU2442773C2 (en) 2012-02-20
KR20080074217A (en) 2008-08-12

Similar Documents

Publication Publication Date Title
NO20083065L (en) New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions
NO20074275L (en) 2- (4-oxo-4H-quinazolin-3-yl) acetamides and their use as vasopressin V3 antagonists
NO20081454L (en) Met kinase inhibitors
NO20082090L (en) Pyridopyrimidinone inhibitors of P13K alpha
NO20073849L (en) Indole derivatives for the treatment of viral infections
NO20063449L (en) Substituted heterocycles and their use
NO20091553L (en) Phenyl derivatives and their use as immunomodulators
NO20082509L (en) Pyridopyrazine derivatives and their use
NO20092053L (en) HCV NS3 protease inhibitors
NO20070487L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
NO20076648L (en) Novel thiophene derivatives
NO20081729L (en) New diazaspiroalkanes and their use in the treatment of CCR8-mediated diseases
NO20070489L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
NO20070081L (en) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related diseases
NO20074634L (en) Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
NO20090755L (en) Amino-imidazolones and their use as a drug for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
NO20060202L (en) Pyrrolodihydroisoquinolines as PDE-10 inhibitors
NO20090628L (en) Pyridizinone derivatives
NO20083214L (en) Pyrimidinylarylurea derivatives which are converted to FGF inhibitors
NO20071504L (en) Pyrimidinderivanter.
NO20081217L (en) New benzothiazole derivatives
NO20075082L (en) Pyridine-3-carboxamide derivatives as CB1 inversion agonists
NO20080879L (en) HCV NS3 protease inhibitors
NO20083427L (en) Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application